The Rheumatologist reports on the results of a multicenter, prospective, open-label study, which found ustekinumab therapy was effective in treating oral ulcers resistant to colchicine in patients with Behçet’s disease.

HSS rheumatologist, Robert F. Spiera, MD, who was not involved in the study, provided commentary on the findings, noting “Refractory oral aphthous ulcerations in patients with Behçet’s disease is a clinical challenge, and the suggestion of efficacy and tolerability of an intervention with which rheumatologists are comfortable offers hope for expanding our therapeutic armamentarium in this disease.” Dr. Spiera added, “There is potentially a need for other therapies for managing this less ‘organ-damaging’ manifestation of the disease, which nevertheless has an important impact on quality of life.”

Read the full article at the-rheumatologist.org.